TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00271362

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Amputation rehabilitation exercise program
Description: participants will be physically exercised with a full array of exercise methodologies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteomyoplasty vs. routine long posterior flap
Description: participants enrolled randomly in one of two surgical procedures.
Study: NCT05032391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)
Description: Three times orally in a volume of 2.5 ml (1 dose)
Study: NCT00630409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 800 mg IV day 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: 24 mg/m2 every 21 days IV
Study: NCT04315545

Intervention type: DIAGNOSTIC_TEST
Intervention: meal tolerance test
Description: In addition to the standard oral glucose tolerance (which is normally performed between 24-28 weeks of pregnancy), is used to test the metabolic resilience capacity of glucose, we will provide our participants with a different diagnostic tool named 'meal tolerance test' in an earlier stage of pregnancy (12-16 weeks), mid pregnancy (24-28 weeks) and 3 months postpartum.
Study: NCT05032391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three times orally in a volume of 2.5 ml (1 dose)
Study: NCT02493829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AML Cell Vaccine
Study: NCT04329273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sliding leg curl
Description: The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition
Study: NCT02600715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (BoNT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Onabotulinumtoxin A (BoNT)
Study: NCT01707563

Intervention type: PROCEDURE
Group type: OTHER
Intervention: skin punch biopsy and molecular biology

Intervention type: OTHER
Group type: OTHER
Intervention: fibroblast culture and molecular biology
Study: NCT03332316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate
Description: Dexamethasone injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate
Description: Dexamethasone injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate
Description: Dexamethasone injection
Study: NCT02600715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belladonna
Description: Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo to B\&O suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active B&O suppository of belladonna
Description: belladonna 16.2mg and morphine 7.5mg
Study: NCT01822886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin + Gemcitabine
Description: Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
Study: NCT03332316

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine Hydrochloride Inj 2 mg/ml
Description: Ropivacaine injection
Study: NCT01227863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxitrol®
Description: Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
Study: NCT02037217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial MRgFUS System
Study: NCT00917488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardization of allergenic extract (Gly. domesticus)
Description: Allergenic extract for cutaneous prick-test
Study: NCT03405428

Intervention type: OTHER
Group type: OTHER
Intervention: Allen test
Description: Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.

Intervention type: OTHER
Group type: OTHER
Intervention: Radial artery diameter measurement by ultrasonography
Description: Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.

Intervention type: OTHER
Group type: OTHER
Intervention: Ulnar artery doppler ultrasonography
Description: Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
Study: NCT01675193

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Disinvestment protocol
Description: Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months
Study: NCT05090852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hi-VNI
Description: Hi-VNI used instead of or along with endotracheal intubation or jet ventilation to provide oxygen to patients during upper airway surgery
Study: NCT01031368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study: NCT03332316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride Inj 2 mg/ml
Description: Ropivacaine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride Inj 2 mg/ml
Description: Ropivacaine injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride Inj 2 mg/ml
Description: Ropivacaine injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection
Study: NCT01031368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo expanded cord blood progenitor cell infusion
Description: Undergo ex vivo-expanded cord blood progenitor cell infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03315416

Intervention type: OTHER
Intervention: Speech Sound Assessment
Description: Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
Study: NCT03332316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection
Study: NCT02065817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope of cholesterol
Study: NCT01447186

Intervention type: BEHAVIORAL
Intervention: Post-Test Questionnaire
Description: Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
Study: NCT04762810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and glucocorticoids
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
Study: NCT01317264

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no β-glucan
Description: daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oat β-glucan
Description: daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: barley β-glucan
Description: daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days
Study: NCT03332316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 9mg/mL
Description: Sodium Chloride injection
Study: NCT01317264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mutant-barley β-glucan
Description: daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days
Study: NCT04027504

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fitabisc
Description: Biscuits containing antioxidants
Study: NCT01490385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED Phototherapy
Study: NCT04435093

Intervention type: OTHER
Intervention: MFM-Play
Description: Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
Study: NCT01633762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem, gentamicin, vancomycin (together)
Description: 4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)
Study: NCT01248429

Intervention type: BIOLOGICAL
Intervention: CPK dosage
Description: CPK dosage during a blood sample realized at least one week after the begining of the treatment

Intervention type: OTHER
Intervention: Clinical exam
Description: Examination of the patient for myalgia, cramps, medical history and concomitant medication
Study: NCT06249074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: Diet with gluten elimination followed by all participants for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten-free diet
Description: Diet with gluten elimination followed by all participants for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten capsules supplementation
Description: 2 g of gluten given in 3 capsules daily for 4 weeks (week 5 to week 8)
Study: NCT03914586

Intervention type: DEVICE
Intervention: oXiris filter
Description: Continuous Renal Replacement Therapy with oXiris filter
Study: NCT02462278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempuRing
Study: NCT03898999

Intervention type: OTHER
Intervention: Overall status
Description: An assessment is made of the participants measuring both the joint range of the ankle and the balance and risk of falls.
Study: NCT00249366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam (drug)
Description: Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam (drug)
Description: Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
Study: NCT00239642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer (iron sucrose injection)
Description: 0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer (iron sucrose injection)
Description: 1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer (iron sucrose injection)
Description: 2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
Study: NCT02948309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mistletoe extract (Iscador Qu)
Description: 1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml subcutaneous injection 3 times/week
Study: NCT03277456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Description: Intramuscular injection of novel vaccine
Study: NCT01313988

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols and fish oil
Description: 4 weeks intervention, 3 times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols and fish oil
Description: 4 weeks intervention, 3 times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols and fish oil
Description: 4 weeks intervention, 3 times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols
Description: 4 weeks intervention, 3 times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks, 3 times daily
Study: NCT06249074

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules supplementation
Description: Rice starch in gastrosoluble capsules given in 3 capsules daily for 4 weeks (week 5 to week 8).
Study: NCT03573921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrograﬁn
Description: Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline solution (control treatment)
Description: Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
Study: NCT01447186

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
Study: NCT01873625

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mesenchymal cell transplantation
Description: Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
Study: NCT03747497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: contezolid acefosamil
Description: IV and oral contezolid acefosamil given twice a day for 10 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid 600 mg
Description: IV and oral linezolid given twice a day for 10 to 14 days
Study: NCT00701064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Light Exposure
Description: Administered via bright light box

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Ion Generator
Description: Administered via Negative Ion Generatore
Study: NCT02186548

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed surgical technique
Description: * Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~* The bone covering the canine is being removed~* Attachment with a chain is bonded to the exposed tooth~* The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~* The canine is orthodontically moved beneath the palatal mucosa

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical technique
Description: * Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~* Pack/filling material is applied on the tooth~* Spontaneous eruption of the palatally impacted canine is allowed expected~* The canine is orthodontically moved above the mucosa
Study: NCT04221165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Opioids will be prescribed as per institutional standards.
Study: NCT03339622

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PPP001
Description: 1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
Study: NCT05124145

Intervention type: OTHER
Intervention: No intervention (surveillance system)
Description: The surveillance network will collect data on all consecutive COVID-19 cases
Study: NCT02291068

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychotherapy treatment
Description: 3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
Study: NCT02185729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: Infusion of Intralipid (soybean-derived fat)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinOleic
Description: Infusion of ClinOleic (olive oil-based)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: Infusion of dextrose (sugar) without fat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline (control)
Description: Infusion of 0.9% normal saline
Study: NCT01953419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed disodium
Description: Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
Study: NCT02164890

Intervention type: OTHER
Group type: OTHER
Intervention: micafungin
Description: This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
Study: NCT01769846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization protocol
Description: Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH \& Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.